NERV — Minerva Neurosciences Share Price
0.000.00%
Last trade - 00:00- $11.89m
- -$9.47m
- 24
- 42
- 35
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.68% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 41.18 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Directors
- Remy Luthringer CHM (60)
- Geoffrey Race PRE (61)
- Frederick Ahlholm CFO (56)
- Joseph Reilly COO (46)
- Devin Smith SVP (53)
- Ramana Kuchibhatla SVP
- Michael Davidson OTH (71)
- William Doyle LED (59)
- Hans Hasler IND (65)
- Jeryl Hilleman IND (63)
- David Kupfer IND (80)
- Fouzia Laghrissi-Thode IND (58)
- Jan van Heek IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 23rd, 2007
- Public Since
- June 25th, 2014
- No. of Shareholders
- 35
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 6,993,406
- Address
- 1601 TRAPELO ROAD, SUITE 284, WALTHAM, 02451
- Web
- https://www.minervaneurosciences.com/
- Phone
- +1 6176007373
- Auditors
- Deloitte & Touche LLP
Upcoming Events for NERV
Q3 2025 Minerva Neurosciences Inc Earnings Release
Similar to NERV
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Minerva Neurosciences share price?
As of Today at 22:04 UTC, shares in Minerva Neurosciences are trading at $1.70. This share price information is delayed by 15 minutes.
How has the Minerva Neurosciences share price performed this year?
Shares in Minerva Neurosciences last closed at $1.70 and the price had moved by -27.66% over the past 365 days. In terms of relative price strength the Minerva Neurosciences share price has underperformed the S&P500 Index by -34.77% over the past year.
What are the analyst and broker recommendations for Minerva Neurosciences?
The overall consensus recommendation for Minerva Neurosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Minerva Neurosciences dividend yield?
Minerva Neurosciences does not currently pay a dividend.
Does Minerva Neurosciences pay a dividend?
Minerva Neurosciences does not currently pay a dividend.
When does Minerva Neurosciences next pay dividends?
Minerva Neurosciences does not currently pay a dividend.
How do I buy Minerva Neurosciences shares?
To buy shares in Minerva Neurosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Minerva Neurosciences?
As of the previous close price of $1.70, shares in Minerva Neurosciences had a market capitalisation of $11.89m.
Where are Minerva Neurosciences shares listed?
Here are the trading details for Minerva Neurosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NERV
What kind of share is Minerva Neurosciences?
Based on an overall assessment of its quality, value and momentum Minerva Neurosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Minerva Neurosciences share price forecast for 2025?
The analyst consensus target price for shares in Minerva Neurosciences is $5.00. That is 194.12% above the last closing price of $1.70.
Analysts covering Minerva Neurosciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.68 for the next financial year.
Find out moreWhat is the trend in the Minerva Neurosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Minerva Neurosciences. Over the past six months, its share price has underperformed the S&P500 Index by -34.82%.
As of the last closing price of $1.70, shares in Minerva Neurosciences were trading -25.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Minerva Neurosciences PE Ratio?
The Minerva Neurosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Minerva Neurosciences?
Minerva Neurosciences' management team is headed by:
- Remy Luthringer - CHM
- Geoffrey Race - PRE
- Frederick Ahlholm - CFO
- Joseph Reilly - COO
- Devin Smith - SVP
- Ramana Kuchibhatla - SVP
- Michael Davidson - OTH
- William Doyle - LED
- Hans Hasler - IND
- Jeryl Hilleman - IND
- David Kupfer - IND
- Fouzia Laghrissi-Thode - IND
- Jan van Heek - IND